6 assets in Primitive Neuroectodermal Tumor

Therapeutic assets addressing Primitive Neuroectodermal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Belzutifan Primitive Neuroectodermal Tumor	José Claudio Casali da Rocha	P2	CCC (53)
Nivolumab Primitive Neuroectodermal Tumor	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
G 207 Primitive Neuroectodermal Tumor	M.D. Anderson Cancer Center	P1	CC (47)
Onc 206 Primitive Neuroectodermal Tumor	Jazz Pharmaceuticals	P1	CC (43)
Zoledronate Primitive Neuroectodermal Tumor	University of Wisconsin, Madison	P1	CC (43)